Practical, step-by-step guides for anyone starting or managing GLP-1 treatment. Learn how to begin safely, what to expect week by week, and how to get the most from your medication with confidence.
Patient Guides
Medicare coverage for GLP-1 medications like semaglutide and tirzepatide is expanding, creating new opportunities for older adults managing obesity or related conditions. This guide breaks down what's actually covered, what you'll likely still pay out of pocket, and how to navigate the system without overpaying.
A recent study suggests newer diabetes and weight loss drugs, including GLP-1 agonists, may be associated with certain autoimmune risks. Here is what the research actually says, what it means for patients considering or currently taking these medications, and the right questions to bring to your doctor.
Generic versions of Ozempic (semaglutide) are generating significant buzz, but the reality of when and how they'll reach patients is more complicated than headlines suggest. This article breaks down what a generic actually means, the current legal and regulatory landscape, and what your practical options are right now if cost is a barrier.
Mounjaro (tirzepatide) is increasingly prescribed to adults over 50, but age brings specific considerations around muscle loss, blood pressure, and drug interactions. This guide covers what older adults need to know before starting, including practical questions to bring to your doctor and cost-saving options.
A rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy has been linked to Wegovy in emerging research. This article breaks down what the condition is, how significant the risk appears to be, and what current and prospective patients should discuss with their doctors.
Emerging research suggests that GLP-1 medications like semaglutide (Wegovy) may do more than promote weight loss - they could also reduce the joint inflammation that drives arthritis. For people managing both obesity and arthritis, this potential dual benefit is worth understanding. Here is what the science currently shows and what questions to bring to your doctor.
GLP-1 medications like semaglutide and tirzepatide were developed to treat diabetes and obesity, but clinical research keeps uncovering additional benefits that go well beyond the scale. From heart protection to kidney health, these drugs are proving to be more complex than anyone expected. Here's what the evidence actually shows.
Stopping Ozempic is more complicated than simply skipping your next injection. From appetite returning within weeks to significant weight regain, here is what the research and real patient experiences show. Understanding what to expect can help you plan a smarter off-ramp.
.avif)
.avif)
